Kiniksa Pharmaceuticals International, plc (KNSA) /
The profitability of Kiniksa Pharmaceuticals International, plc over the past 9 years
Chart Kiniksa Pharmaceuticals International, plc: gross profit, operating income, net income, fiscal 2017–2025 Open the chart →Kiniksa Pharmaceuticals International, plc reported net income of $59.01M in fiscal 2025, the latest fiscal year on file. That year it had gross profit of $599.89M and operating income of $77.22M. It reported a profit in 3 of the 9 years shown, and a loss in fiscal 2017, 2018, 2019, 2020, 2021 and 2024. Its highest net income in these years was $183.36M, in fiscal 2022.
Year by year
| Fiscal year | Gross profit | Operating income | Net income |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $599.89M* | $77.22M | $59.01M |
| 2024ended Dec 31, 2024 | $362.33M* | -$45.62M | -$43.19M |
| 2023ended Dec 31, 2023 | $236.85M* | -$25.2M | $14.08M |
| 2022ended Dec 31, 2022 | $197.28M* | $9.77M | $183.36M |
| 2021ended Dec 31, 2021 | $29.44M* | -$156.64M | -$157.92M |
| 2020ended Dec 31, 2020 | — | -$157.36M | -$161.38M |
| 2019ended Dec 31, 2019 | — | -$169.96M | -$161.87M |
| 2018ended Dec 31, 2018 | — | -$108.16M | -$103.23M |
| 2017ended Dec 31, 2017 | — | -$65.4M | -$64.87M |
Fiscal years as Kiniksa Pharmaceuticals International, plc reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Kiniksa Pharmaceuticals International, plc
- The revenue of Kiniksa Pharmaceuticals International, plc
- The cash flow of Kiniksa Pharmaceuticals International, plc
- The debt of Kiniksa Pharmaceuticals International, plc
- All of Kiniksa Pharmaceuticals International, plc's financials, charted
Companies of a similar size
- CAVACAVA Group, Inc.
- WFRDWeatherford International plc
- MSMMSC INDUSTRIAL DIRECT CO., INC.
- KVYOKlaviyo, Inc.
- DOCSDoximity, Inc.
Not investment advice. This page shows what Kiniksa Pharmaceuticals International, plc filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.